Company Analysis
Sign in

China SXT Pharmaceuticals, Inc. (SXTC)

Nasdaq: SXTC · Pharmaceutical Preparations · Taizhou · filing with the SEC since 2017
Full chart Alerts Compare
Grade3.3
◀ Past 2.5● Present 4.1▶ Future 3.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2026, as filed
Revenue$1.1M-34.6%
Net income-$6.2M-87.8%
Earnings per share$-9.13+97.4%
Operating cash flow-$4.0M-71.3%
Cash$28.2M+55.4%
Debt$644,390+569.4%
Shareholders’ equity$29.7M+92.4%
Shares, diluted679,648+7062.5%
Return on equity-20.9%
The recordfrom its filings
Filings in 202628
Newest filingOct 21 · 6-K
Annual reportJul 1, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
17181920212223242526
As filed, in USD. Nothing here is a forecast.

News

Oct 15, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton SXTC · research, not advice